Psoriasin, which is highly expressed in psoriasis, is encoded by a gene located within the epidermal differentiation complex. The aim of this study was to investigate the effect of endogenous psoriasin on disturbed keratinocyte differentiation in psoriasis. Immunohistochemical staining revealed a gradient of psoriasin expression in the psoriatic epidermis with highest expression in the suprabasal, differentiated layers. Induction of keratinocyte differentiation caused concurrent expression of psoriasin and the differentiation marker involucrin. The differentiation-induced psoriasin expression was found to be mediated by the protein kinase C pathway. The downregulation of psoriasin expression by small interfering RNA revealed that psoriasin mediates the expression of involucrin, desmoglein 1, transglutaminase 1 and CD24 in normal differentiation. The lentivirus-mediated overexpression of psoriasin, mimicking the psoriatic milieu, gave rise to an altered regulation of differentiation genes and an expression pattern reminiscent of that in psoriatic epidermis. These findings suggest that psoriasin contributes to the dysregulated differentiation process in the psoriatic epidermis.

Key words: psoriasin; S100A7; differentiation; keratinocyte; psoriasis.

Accepted Dec 12, 2016; Epub ahead of print Dec 13, 2016


Corr: Charlotta Enerbäck, Ingrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Linköping University, SE-581 85 Linköping, Sweden. E-mail: charlotta.enerback@liu.se

To establish the skin barrier and the epidermal structure, keratinocytes undergo a tightly regulated process of differentiation. In this process, the keratinocytes progress from the basal layer of the epidermis through distinct stages to form the spinous, granular and cornified layers. Each of these layers is characterized by specific features in terms of gene expression, function and cellular morphology (1).

In psoriasis, the differentiation process of the epidermal cells is disturbed. The keratinocytes in active psoriatic lesions display an altered sequence and altered expression levels of the differentiation markers (2). However, the mediators that are responsible for the dysregulated differentiation of psoriatic keratinocytes have not been identified.

Psoriasin (S100A7) was first identified for its overexpression in psoriatic keratinocytes (3), where it was found to be located to the nucleus and the cytoplasm (4). Later studies have demonstrated secretion of psoriasin from epithelial cells (5). Intracellular psoriasin has been found to interact with various signalling proteins, including the nuclear factor (NF)-κB regulator Jαb1, while secreted psoriasin functions as an antimicrobial peptide and has the ability to induce chemotaxis of neutrophils and T cells (6). Psoriasin is strongly induced by interleukin (IL)-22 and by the combination of IL-17 and tumour necrosis factor (TNF)-α, which emphasizes the role of psoriasin in the pathogenesis of psoriasis (7). We have shown previously that extracellular psoriasin binds to the receptor for advanced glycation end products (RAGE), promoting endothelial cell proliferation (8). In addition to the low expression in normal skin and the high expression in the psoriatic epidermis, psoriasin is also expressed in conditions displaying abnormal differentiation. In a spectrum of conditions of dysregulated keratinocyte differentiation, we have previously demonstrated strong psoriasin expression in differentiated squamous cell carcinoma and a lack of expression in undifferentiated basalioma (9). This pattern of expression suggests an involvement in epithelial differentiation. In addition, the gene that encodes psoriasin is positioned within the epidermal differentiation complex (EDC) (10–12), a gene cluster that contains several genes of importance in the terminal differentiation of the human epidermis (10, 11).

The high expression level in psoriatic epidermis in conjunction with the disturbed differentiation process suggests that psoriasin is involved in keratinocyte differentiation. Previous studies of the role of psoriasin in keratinocyte differentiation have focused on the effects of extracellular psoriasin, but as the psoriasin in psoriasis is keratinocyte-derived, it is imperative to consider the effects of psoriasin as an endogenously produced intracellular mediator. The aim of this study was therefore to investigate the effect of keratinocyte-derived, intracellular psoriasin on keratinocyte differentiation.

METHODS

Cells and culture conditions

Neonatal human epidermal keratinocytes (HEKn; Life Technologies, Carlsbad, CA, USA), were cultured in EpiLife medium supplemented with 1% EpiLife defined growth supplement (EDGS), 0.06 μM CaCl₂, (Gibco, Paisley, UK) and 1% penicillin/streptomycin (PAA Laboratories, Pasching, Austria). The keratinocyte cell line NTERT-2G was grown in keratinocyte serum-free medium (KFSM, Gibco) as described previously (13). Extracellular treat-
ment with psoriasin (Abnova, Taipei, Taiwan) was conducted with 0.15 μg/ml or 1 μg/ml for 72 h.

**Immunohistochemistry**

Skin punch biopsies were obtained from healthy controls and lesional psoriasis skin and were fixed and paraffin-embedded. The sections were deparaffinized in Histolab-clear (Histolab Products, Gothenburg, Sweden) and rehydrated in ethanol. Heat-induced antigen retrieval was performed in citrate (pH=6) antigen retrieval buffer (DAKO, Glostrup, Denmark). Endogenous peroxidases were blocked with 3% hydrogen peroxide, and unspecific protein binding was inhibited with 5% bovine serum albumin. Antibody binding with primary mouse anti-human psoriasin antibody (1:400; Imageix, San Diego, CA, USA) was carried out overnight at 4°C. Following incubation, DAKO EnVision anti-mouse HRP-conjugated polymer was applied, and antigen-antibody complexes were visualized by DAB-staining (PolySciences, Eppelheim, Germany). Cell nuclei were counterstained with haematoxylin (Invitrogen, Paisley, UK).

**Induction of keratinocyte differentiation**

Keratinocyte differentiation was induced by treating HEKn with CaCl₂, or 12-O-tetradecanoylphorbol-13-acetate (TPA) or by culturing HEKn in suspension or confluence. Differentiation was confirmed by measuring involucrin. For differentiation with CaCl₂ or TPA, HEKn were treated with 2 mM CaCl₂ (Sigma-Aldrich, St Louis, MO, USA) or 1 μM TPA (Acros Organics, Geel, Belgium) for 48 h. For suspension culture, 24-well plates were coated with poly-HEMA. The cells were seeded in complete EpiLife and harvested after 24 or 48 h. For differentiation in confluence, cells were seeded at near-confluence in complete EpiLife medium. Upon cell confluence, the culture medium was substituted for EDGS-free EpiLife medium and cells were grown without any additional change of medium for 5 or 7 days.

**Signal pathway inhibitors**

To investigate the participation of the protein kinase C (PKC) pathway, HEKn were pre-treated with the PKC-inhibitor bisindolylmaleimide I (4 μM, Cell Signalling, Danvers, MA, USA), or the PKC-δ inhibitor rottlerin (4 μM, Cell Signalling) for 30 min followed by treatment with CaCl₂. An equal volume of dimethyl sulfoxide (DMSO) was included in non-inhibitor wells as vehicle control.

**Small interfering RNA (siRNA)**

To down-regulate psoriasin expression, HEKn were transfected with psoriasis-siRNA (Pso-siRNA) or a validated non-targeting siRNA (C-siRNA) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Following transfection, the cells were treated with 2 mM CaCl₂ for 48 h.

**Apoptosis detection assay**

Apoptosis was analysed by the FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, San Jose, CA, USA), staining cells with Annexin V-FITC and propidium iodide (PI). Cell staining was analysed using a Gallios flow cytometer and Kaluza analysis software (Beckman Coulter, Brea, CA, USA). Annexin V+PI+ cells were considered to be viable, Annexin V+PI− cells apoptotic and Annexin V−PI− cells necrotic.

**Generation of psoriasin-overexpressing keratinocytes**

Human NTERT keratinocytes with a sustained overexpression of psoriasin were generated as described previously (14). Briefly, total RNA was extracted from psoriatic skin biopsies and cDNA was synthesized. Psoriasin (NM_002963) was amplified by PCR and subsequently cloned into the lentiviral expression vectors pLent6.3/TO/V5-DEST and used to produce infectious lentivirus particles.

**RNA extraction, cDNA synthesis and quantitative real-time PCR**

The RNaseq mini kit (Qiagen, Hilden, Germany) was used to extract RNA. cDNA was synthesized using the Maxima First Strand cDNA Synthesis Kit (Fermentas, Vilnius, Lithuania). qPCR was performed with the SYBR green (Applied Biosystems, Foster city, CA, USA) on a real-time 7500HT or 7900HT PCR (Applied Biosystems). Primers for psoriasin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were designed as described (15–18). Primers for ribosomal protein large p0 (RPLP0), cytokeratin (K)1, K10, involucrin, filaggrin, desmoglein (Dsg)-1, desmocollin (Dsc)-1, transglutaminase (TGM)-1 and CD24 were designed using the Primer Express Software version 3.0 (Applied Biosystems) (Table I). Expression data were normalized to RPLP0 as GAPDH as indicated, using the comparative C₅₇ method.

**Immunofluorescence**

Keratinocytes were fixed in 4% paraformaldehyde and permeabilized with 0.1% saponin. The cells were incubated overnight at 4°C with monoclonal mouse anti-human anti-psoriasin (Abcam, Cambridge, UK), followed by incubation with secondary goat anti-mouse AlexaFluor555 (Molecular Probes, Eugene, OR, USA). Nuclei were counterstained with DAPI (4’,6-diamidino-2-phenylindole). Staining was evaluated in an AxioVert.A1 Microscope (Zeiss, Oberkochen, Germany). Negative controls were obtained by omitting the primary antibody and only incubate the sections with secondary antibody. These controls displayed no staining.

**Removal of epidermis**

To determine the co-occurrence of psoriasin, S100A8, S100A9 and S100A12 in psoriasis, skin punch biopsies, 4-mm in diameter, were obtained from age- and sex-matched patients with psoriasis and from healthy controls. A total of 9 biopsies, consisting of 3 involved (PP), 3 uninvolved (PN) and 3 normal (NN) skin biopsies, were obtained. The epidermis was detached by soaking the biopsy in 0.15 µg/ml or 1 µg/ml for 72 h. Immunofluorescence with psoriasin (Abnova, Taipei, Taiwan) was conducted with

**Gene expression microarray**

RNA extracted from 3 psoriasin-overexpressing or control NTERTs or from PP, PN and NN epidermis was used to generate Table I. Primer sequences used for quantitative real-time PCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer</th>
<th>Reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psoriasin (S100A7)</td>
<td>tggtagttgctgcgtactftcctcc</td>
<td>gatagatagacatgtttcacaata</td>
</tr>
<tr>
<td>Keratin 1</td>
<td>gccctgaacacacacccatag</td>
<td>gcgggagaaaggtggtcctt</td>
</tr>
<tr>
<td>Keratin 10</td>
<td>gaggggagaaacagctcatctag</td>
<td>gctgcctcggcctctgctg</td>
</tr>
<tr>
<td>Involucrin</td>
<td>cctactaggaccaaatagaaacag</td>
<td>gcgggagaaaggtggtcctt</td>
</tr>
<tr>
<td>Filaggrin</td>
<td>gagctcaagaggaaacaaag</td>
<td>ggacggatgacatctcaataca</td>
</tr>
<tr>
<td>Desmoglein 1</td>
<td>tccatatttttgtatagtgttgtg</td>
<td>gatctcaacagctgatcata</td>
</tr>
<tr>
<td>Desmocollin 1</td>
<td>tcataggtgctgtggctctc</td>
<td>ccgctgactgtactaat</td>
</tr>
<tr>
<td>Transglutaminase 1</td>
<td>cccgctgtgtgtcatcaca</td>
<td>gacgaggaaggcagcagaga</td>
</tr>
<tr>
<td>CD24</td>
<td>tttcattttgttgcatttgctt</td>
<td>ttcacagctgagggagaa</td>
</tr>
<tr>
<td>GAPDH</td>
<td>cagggccggcaaatag</td>
<td>ccacagctgagcactgatc</td>
</tr>
<tr>
<td>Ribosomal protein.large.p0</td>
<td>actgtgcagccgacgaaca</td>
<td>agcgtggaagggagtcttc</td>
</tr>
</tbody>
</table>

GAPDH: glyceraldehyde 3-phosphate dehydrogenase.
hybridization probes using the GeneChip® WT PLUS Reagent kit according to the manufacturer’s instructions. Hybridization to GeneChip® human transcriptome arrays 2.0 was performed in a GeneChip® hybridization oven, followed by washing and staining in a GeneChip® Fluidics Station 450 and scanning in a GeneChip® Scanner 3000 7G system. Expression Console software (v1.2.1) was used to verify the quality controls. All GeneChip® products were from Affymetrix (Santa Clara, CA, USA). CEL-files generated by the Affymetrix AGCC program were analysed using Genespring GX software (v13.0; Agilent Technologies, Santa Clara, CA, USA). A Standard Robust Multi-Array Average (RMA) normalization and background correction was performed. The probe sets were filtered on expression with a 20th percentile cut-off. The fold change was computed by the GeneSpring software. On the probe sets that remained after the filtering, a 1.5-fold change was applied as a cut-off for up- and down-regulated genes. To determine the co-expression of S100 proteins, a heatmap was constructed in R (version 3.2.4) and clustering was performed based on normalized data.

Statistical analysis
The data are presented as the mean ± standard error of mean (SEM), and were compared using paired Student’s t-test or Wilcoxon signed-rank test. Analyses were performed using GraphPad Prism 6 software (GraphPad software, La Jolla, CA, USA). A value of \( p < 0.05 \) was considered statistically significant.

RESULTS
Psoriasin is expressed as a gradient in psoriatic skin
Psoriasin was originally identified as a protein highly expressed in lesional psoriatic skin (3). To describe the differential expression pattern between patients with psoriasis and healthy controls, we performed immunohistochemistry and obtained a sparse psoriasin expression in normal skin (Fig. 1a) that was not noticeably different from the negative control (Fig. 1c). In the lesional psoriatic skin, we observed a pronounced staining (Fig. 1b) with a tendency for a psoriasin gradient, ranging from weak expression in the basal cell layer to intense expression in the more differentiated layers of the epidermis. This pattern of psoriasin expression suggests the involvement of psoriasin in later stages of keratinocyte differentiation.

![Fig. 1. Psoriasin is expressed as a gradient in the psoriatic skin.](image-url)

Exogenous psoriasin increases involucrin and psoriasin expression
An effect of extracellular, exogenous psoriasin on keratinocyte differentiation has been previously suggested by Hattori et al. (19) and by Son et al. (20). To examine the effects in our culture system, HEKn were treated with psoriasin and the expression of involucrin and psoriasin were investigated. It was found that exogenous psoriasin increased involucrin, but also that it caused up-regulated psoriasin expression, suggesting that extracellular psoriasin may induce intracellular production in an autocrine fashion (Fig. 2a). We did not observe any change in cell morphology upon psoriasin treatment, suggesting that extracellular psoriasin may be unable in itself to induce differentiation.

Keratinocyte differentiation induces psoriasin expression
To evaluate whether a relationship between psoriasin and differentiation rather than merely a co-occurrence of gradients exists, psoriasin expression was evaluated in cells exposed to differentiation-inducing conditions. Keratinocytes were treated with calcium, TPA or were cultured in suspension or confluence, all of which are established differentiation methods (21–24). All these conditions induced the expression of both psoriasin and involucrin (Fig. 2b). In conclusion, we found that psoriasin is endogenously produced in keratinocytes in response to differentiation.

Differentiation-induced psoriasin expression is regulated by protein kinase C
PKC has been implicated in the regulation of keratinocyte differentiation (25) and inhibitors of the PKC-δ pathway block the calcium-induced expression of involucrin (26). To further evaluate the role of endogenous psoriasin in keratinocyte differentiation we investigated the effect of PKC inhibitors in differentiated keratinocytes. Keratinocytes with intact PKC signalling displayed induced
expression of psoriasin and involucrin on calcium treatment. Treatment with the general PKC inhibitor bisindolylmaleimide (Fig. 2c) or with rottlerin (Fig. 2d), a specific PKC-δ inhibitor, markedly reduced the expression both of psoriasin and involucrin. These results demonstrate that PKC-δ is involved in the enhanced psoriasin expression in keratinocyte differentiation.

Psoriasin is a mediator in the normal differentiation process in keratinocytes

To determine whether psoriasin is part of the keratinocyte differentiation pathway, or merely simultaneously induced, cells were transfected with siRNA. The successful down-regulation of psoriasin expression using siRNA was

Fig. 2. The endogenous psoriasin expression upon differentiation is regulated by the protein kinase C (PKC) pathway. (a) To determine the effects of exogenous psoriasin, neonatal human epidermal keratinocytes (HEKn) were treated with psoriasin at concentrations of 0.15 µg/ml and 1 µg/ml for 72 h. (b) To examine the effect of endogenous psoriasin expression for differentiation, HEKn were treated with 2 mM CaCl₂ for 48 h or 1 µM tetradecanoylphorbol-13-acetate (TPA) for 48 h or cultured in suspension or in confluence. Calcium and TPA treatment both induced the expression of psoriasin and involucrin. Psoriasin and involucrin expression was also induced in cells cultured in suspension or in confluence. Expression levels are shown as relative fold induction compared with untreated control, using RPLP0 as the internal control. To further study the role of PKC, HEKn were pre-treated with 4 µM of (c) the general PKC-inhibitor bisindolylmaleimide I, (d) the PKC-δ-specific inhibitor rottlerin, or vehicle DMSO for 30 min, followed by treatment with 2 mM CaCl₂ for 48 h. CaCl₂ induced mRNA expression of psoriasin and involucrin, was reduced by the inhibition of PKC. Expression levels are shown as relative fold induction compared with untreated control using RPLP0 as the internal control. Data are displayed as mean ± SEM, n = 6; *p < 0.05, **p < 0.01.
confirmed by qPCR (Fig. 3a). The differentiation process was induced using calcium, which triggered the expression of the differentiation markers filaggrin, DSG-1, DSC-1, TGM-1 and CD24 (Fig. 3b–g). Furthermore, calcium treatment induced the expression of K1 and K10 (data not shown). The down-regulation of psoriasin resulted in a significantly diminished expression of involucrin (Fig. 3b), DSG-1 (Fig. 3d), TGM-1 (Fig. 3f) and CD24 (Fig. 3g). The expression of filaggrin was decreased, but did not reach statistical significance (Fig. 3c). No effect of the down-regulation was seen on the differentiation markers DSC-1 (Fig. 3c), K1 or K10 (data not shown), suggesting that the importance of psoriasin on the differentiation process may vary in different stages of differentiation. This suggests that endogenous psoriasin is an important mediator during the later stages of keratinocyte differentiation.

Down-regulation of endogenous psoriasin expression does not affect cell viability or morphology

The down-regulation of psoriasin expression by siRNA did not alter cellular morphology and did not affect cell proliferation compared with control cells (data not shown). Likewise, we did not see any difference in either apoptosis or necrosis in siRNA-treated keratinocytes compared with control cells (data not shown). This supports the results we observed with the extracellular psoriasin, again indicating that psoriasin does not, on its own, induce differentiation, nor does it affect apoptosis. It also confirms that the effects we see are not due to increased cell toxicity.

Overexpression of psoriasin leads to dysregulated keratinocyte differentiation

To evaluate the effect of a high expression of psoriasin, as seen in psoriasis, keratinocytes with a sustained overexpression were generated. Immunofluorescence demonstrated a strong staining in the vector-transfected keratinocytes, but no staining in non-transfected cells (Fig. 4a). The transfection did not affect the cell morphology (Fig. 4b). Using microarray, we found a profound effect of psoriasin overexpression on mRNA transcripts related to differentiation. Interestingly, among the top 5 most down-regulated genes in the microarray of psoriasis-overexpressing keratinocytes compared with control cells, 4 are associated with differentiation, namely DSG-1, CASP14, K10 and DSC-1 (Table II). Among the top 15 most down-regulated genes, we observed the differentiation-regulating genes TGM-1, K1, FOXN1 and the SPRR1A gene. Among the up-regulated genes in the microarray in the psoriasis-overexpressing cells, the gene coding for involucrin was found to be the 11th most upregulated gene. Furthermore, the overexpression of psoriasin was also found to cause an up-regulation of IL1B and K16 and a down-regulation of CXCL14. These results support that psoriasin has a dysregulating
function on keratinocyte differentiation. Keratinocytes that overexpressed psoriasin also exhibited a significantly lower proliferation than control keratinocytes (Fig. 4c), strengthening that these cells undergo differentiation with the accompanying decrease in proliferation.

Psoriasis (S100A7), S100A8, S100A9 and S100A12 are co-expressed in psoriasis

Psoriasis is part of a family of S100-proteins with high sequence homology. To determine whether other proteins in this family share the expression pattern of psoriasin in psoriasis, we constructed a heatmap, comparing the expression of S100-proteins between lesional psoriasis, non-lesional psoriasis and healthy epidermis. We found a strong co-clustering of psoriasin and S100A8, S100A9 and S100A12, suggesting a co-regulation of these proteins (Fig. 4d).

DISCUSSION

Keratinocyte differentiation is coordinated by an intricate sequence of gene activation (27). Several markers of differentiation have been identified in epidermal keratinocytes, with involucrin being the most established. The expression of involucrin commences in the upper spinous layer and continues through the granular layer (28) in a similar localization pattern as TGM-1 (29). In contrast, K1 and K10 are considered markers of early differentiation (30). The stratum corneum is marked by the expression of filaggrin (31). CD24 is most prominent in differentiated mammary epithelium (32, 33), but has also been detected in the upper, more differentiated layers of human epidermis (34).

Psoriasis is characterized by an epidermal thickening with an absence of the granular layer and a thickened and irregular cornified layer. Some differentiation markers, including involucrin and TGM, appear prematurely in the lower layers of the psoriatic epidermis, while other markers, such as filaggrin, are either absent or found in the cornified layer. The expression levels of several markers are abnormal, with some markers, including involucrin, demonstrating an overexpression (2, 35), and others, such as K1 and K10, being down-regulated (36).

Previous studies that have attempted to elucidate the role of psoriasin in keratinocyte differentiation have focused on the effects of extracellular, exogenous psoriasin, with conflicting results. While Hattori et al. (19) demonstrated up-regulation of differentiation markers after psoriasin treatment, Son et al. (20) suggested that exogenous psoriasin may negatively regulate differentiation. The findings by Hattori et al. are in line with the increase in involucrin that we observe upon psoriasin treatment. Applying several methods of induction of dif-

Table II. The top 15 most up-regulated and down-regulated differentially expressed genes in psoriasin-overexpressing NTERTs compared with control NTERTs

<table>
<thead>
<tr>
<th>Up-regulated genes</th>
<th>Fold change</th>
<th>Down-regulated genes</th>
<th>Fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOC730755</td>
<td>KRTAP2-4</td>
<td>4.55</td>
<td>DSG1</td>
</tr>
<tr>
<td>FTHLH</td>
<td>2.52</td>
<td>CASP14</td>
<td>-7.86</td>
</tr>
<tr>
<td>PDCD1LG2</td>
<td>2.12</td>
<td>CXCL14</td>
<td>-7.14</td>
</tr>
<tr>
<td>MR6141</td>
<td>GPRCSA</td>
<td>2.10</td>
<td>KRT10</td>
</tr>
<tr>
<td>MMP10</td>
<td>2.08</td>
<td>DSC1</td>
<td>-3.25</td>
</tr>
<tr>
<td>DKK1</td>
<td>2.07</td>
<td>C10orf99</td>
<td>-3.01</td>
</tr>
<tr>
<td>TNFAIP3</td>
<td>2.00</td>
<td>EGR1</td>
<td>-2.80</td>
</tr>
<tr>
<td>ITGB6</td>
<td>1.98</td>
<td>FOXN1</td>
<td>-2.63</td>
</tr>
<tr>
<td>IL1B</td>
<td>1.97</td>
<td>ALOX1S5</td>
<td>-2.52</td>
</tr>
<tr>
<td>NCCR1P1</td>
<td>1.95</td>
<td>TGM1</td>
<td>-2.45</td>
</tr>
<tr>
<td>IVL</td>
<td>1.93</td>
<td>BCAM</td>
<td>-2.39</td>
</tr>
<tr>
<td>LCPL</td>
<td>1.92</td>
<td>SLC7A8</td>
<td>-2.39</td>
</tr>
<tr>
<td>HEPH1</td>
<td>1.91</td>
<td>KRT1</td>
<td>-2.38</td>
</tr>
<tr>
<td>HSD11B1</td>
<td>1.90</td>
<td>SPPR1A</td>
<td>-2.37</td>
</tr>
<tr>
<td>ALDH1A3</td>
<td>1.89</td>
<td>IGFL1</td>
<td>-2.30</td>
</tr>
</tbody>
</table>

*Differentiation-related genes.
Psoriasis contributes to dysregulated differentiation in psoriasis

Psoriasin contributes to dysregulated differentiation in psoriasis

In conclusion, this study demonstrates that psoriasin affects keratinocyte differentiation in a concentration-dependent manner. In the normal differentiation process, psoriasin regulates the expression of several intermediate and late differentiation markers. However, when overexpressed at pathologically relevant levels, the effects are different than those seen upon induction in normal skin, yielding an expression pattern of differentiation markers that resembles that seen in lesional psoriatic skin. While psoriasin does not on its own induce differentiation, it is clear that it acts as a modulator. Instead of merely acting as a positive or negative regulator of differentiation, psoriasin appears to skew the process. These findings suggest that psoriasin is a prominent contributor to the dysregulated differentiation process that has been established in the psoriatic epidermis.

ACKNOWLEDGEMENTS

The authors would like to thank Stefan Stoll for help with generating the psoriasin-overexpressing NTERTs.

This research was funded by the Ingrid Asp Foundation, the Welander Foundation, the Swedish psoriasis association and the Medical Research Council.

The authors declare no conflicts of interest.

REFERENCES

8. Shubbar E, Vegfors J, Carlstrom M, Petersson S, Enerback...
C. Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Res Treat 2012; 134: 71–80.


